顺铂联合替莫唑胺治疗复发性恶性脑胶质瘤临床研究

Clincal study on cisplatin combined with temozolomide in the treatment of recurrent malignant glioma

目的探讨顺铂联合替莫唑胺治疗复发性恶性脑胶质瘤患者的疗效及对其生活质量的影响。方法选取我院63例复发性恶性脑胶质瘤患者随机分组,对照组31例,观察组32例,对照组予以替莫唑胺治疗,观察组予以顺铂+替莫唑胺治疗,观察比较临床疗效、生活质量评分及不良反应发生情况。结果观察组缓解率为71.88%(23/32)、控制率为87.50%(28/32),高于对照组45.16%(14/31)、64.52%(20/31),差异具有统计学意义(P<0.05);治疗后观察组生活质量各指标评分均高于对照组,差异具有统计学意义(P<0.05);观察组不良反应发生率为21.88%(7/32),对照组为12.90%(4/31),组间对比差异无统计学意义(P>0.05)。结论顺铂联合替莫唑胺治疗复发性恶性脑胶质瘤,疗效显著,可有效改善患者生活质量,安全性高。

Objective To evaluate the efficacy of cisplatin combined with temozolomide in the treatment of recurrent malig nant glioma and its influence on the quality of life. Methods 63 cases of recurrent malignant glioma in our hospital were randomly divided into control group（n 31） and observation group（n=32）. The control group was treated with temozolomide,and the ob servation group was treated with cisplatin combined with temozolomide. The clinical efficacy,quality of life score and adverse reac tions were observed and compared. Results The remission rate of the observation group 71.88% （23/32） and the control rate 87.50% （28/32）,which were higher than those of the control group 45.16% （14/31） and 64.52%（20/31）,the difference was statistically significant （P〈0.05）. After treatment,the quality of life indicators in the observation group were higher than those in the control group,the difference was statistically significant （P〈0.05）. The incidence of adverse reactions was 21.88% （7/32） in the observation group and 12.90% （4/31）in the control group. There was no significant difference between the two groups （P〈 0.05）.Conclusion Cisplatin combined with temozolomideis effective in the treatment of recurrent malignant glioma. It can effec tively improve the quality of life of patients with high safety.